Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mutant KRAS Neoantigen (mKRAS neoantigen)
- Target
- mKRAS neoantigen
- Molecular classification
- Peptide, Neoantigen, MHC-presented antigen
01
Overview
Mutant KRAS neoantigens are tumor-specific antigens derived from mutated KRAS proteins, primarily at codon 12. These neoantigens are presented on the cell surface via MHC class I molecules and serve as targets for immunotherapeutic strategies such as adoptive T-cell therapy and bispecific antibodies. Their tumor specificity and immunogenicity make them attractive targets for treating KRAS-mutant cancers.
- Other names
- Mutated KRAS NeoantigenKRAS G12D NeoantigenKRAS G12V NeoantigenKRAS NeoepitopemKRAS peptide-HLA complex
02
Mechanism of action
TCR-mediated recognition and killing of cancer cells
03
Biological functions
T-cell activationImmune responseTumor antigen presentation
04
Disease associations
CancerTumor immunology
05
Safety considerations
Off-target toxicityCytokine release syndrome (CRS)Graft-versus-host disease (GvHD)Tumor lysis syndrome (TLS)Immune-related adverse events (irAEs)
06
Biomarkers
KRAS mutation status (G12D, G12V, G12C, G12R)HLA type (HLA-C*08:02, HLA-A*11:01)TCR clonalityTumor mutational burden (TMB)PD-L1 expression
Beyond the preview
Go deeper on Mutant KRAS Neoantigen (mKRAS neoantigen).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mutant KRAS Neoantigen (mKRAS neoantigen).